AC
LCTX icon

Aristides Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Aristides Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$154K – 182
2022
Q1 		$154K Buy
+100,000
New +$155K 0.09% 162

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aristides Capital's LCTX Position: Q2 2022 in Review

Aristides Capital sold out of Lineage Cell Therapeutics (LCTX) in Q2 2022, closing a stake of 100,000 shares — an estimated $154K sold.

Aristides Capital first reported a position in LCTX in Q1 2022 and held it in 1 quarter. The position peaked at $154K in Q1 2022. 101 funds tracked by Wall St. Rank hold LCTX as of Q2 2022.

  • Aristides Capital reported no remaining Lineage Cell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Aristides Capital sold 100,000 Lineage Cell Therapeutics shares in Q2 2022, an estimated $154K.
  • Aristides Capital first reported a position in Lineage Cell Therapeutics in Q1 2022 and held it in 1 quarter.
  • Aristides Capital's Lineage Cell Therapeutics position peaked at $154K in Q1 2022.
  • 101 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2022.

Based on Aristides Capital's 13F filing for Q2 2022, filed 15 Aug 2022.